Table 3.
Principal analysis: patient-reported outcome comparisons (LOCF)
| Week 12, placebo-adjusted | Week 24 | Week 48 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| ADA 40 mg (ADA, n = 151; PBO, n = 162) | SEC 150 mg (SEC, ESS = 36; PBO, ESS = 27) | SEC 300 mg (SEC, ESS = 38; PBO, ESS = 27) | ADA 40 mg (n = 151) |
SEC 150 mg (ESS = 36) |
SEC 300 mg (ESS = 38) |
ADA 40 mg (n = 151) |
SEC 150 mg (ESS = 36) |
SEC 300 mg (ESS = 38) |
|
| HAQ-DI score | − 0.30 (− 0.41, − 0.19) | − 0.20 (− 0.32, − 0.09) | − 0.24 (− 0.36, − 0.12) | − 0.40 (− 0.48, − 0.32) | − 0.53 (−0.62, −0.43) P = 0.046a | − 0.52 (− 0.61, − 0.42) | − 0.40 (− 0.48, − 0.32) | − 0.54 (− 0.64, − 0.44) P = 0.037a | − 0.52 (− 0.62, − 0.41) |
| PGA (0–10 cm) | − 20.0 (− 25.9, − 14.1) | − 25.8 (− 32.4, − 19.1) | − 25.2 (− 32.1, − 18.4) | − 21.1 (− 25.8, − 16.4) | − 30.2 (− 34.6, − 25.9) P = 0.005a | − 27.9 (− 32.9, − 22.9) | − 22.4 (− 25.6, − 19.2) | − 27.5 (− 32.4, − 22.6) | − 29.4 (− 34.1, − 24.7) P = 0.016a |
| Pain (VAS) | − 24.6 (− 30.3, − 18.9) | − 18.9 (− 25.4, − 12.3) | − 15.6 (− 22.7, − 8.5) | − 24.0 (− 28.5, − 19.5) | − 30.4 (− 34.6, − 26.3) P = 0.039 a | − 24.5 (− 29.4, − 19.5) | − 24.0 (− 27.1, − 20.9) | − 27.7 (− 32.5, − 22.9) | − 27.9 (− 33.0, − 22.8) |
| FACIT-Fatigue scorec | 5.9 (3.7, 8.1) | 8.8 (6.3, 11.2) | 6.2 (3.5, 8.8) | 7.1 (5.5, 8.7) | 7.8 (6.1, 9.6) | 4.5 (3.0, 6.0) P = 0.021 b | 6.7 (5.6, 7.8) | 7.6 (6.1, 9.1) | 5.6 (4.0, 7.1) |
Data are shown as mean change from baseline (95% confidence interval)
ADA adalimumab, ESS effective sample size, FACIT Functional Assessment of Chronic Illness Therapy, HAQ-DI Health Assessment Questionnaire Disability Index, LOCF last observation carried forward, PBO placebo, PGA patient’s global assessment, SEC secukinumab, VAS visual analog scale
aStatistical significance in favor of SEC
bStatistical significance in favor of ADA
cWeek 48 FACIT-Fatigue score comparisons were made between week 48 (ADEPT) and week 52 (FUTURE 2)